NASDAQ: LMAT
Lemaitre Vascular Inc Stock

$79.00-26.78 (-25.32%)
Updated Aug 5, 2026
LMAT Price
$79.00
Fair Value Price
$121.69
Market Cap
$1.81B
52 Week Low
$78.65
52 Week High
$118.01
P/E
28.62x
P/B
4.44x
P/S
9.71x
PEG
3.16x
Dividend Yield
1.14%
Revenue
$256.28M
Earnings
$62.40M
Gross Margin
72.4%
Operating Margin
33.48%
Profit Margin
24.3%
Debt to Equity
0.55
Operating Cash Flow
$87M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

LMAT Overview

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LMAT's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
B
LMAT
Ranked
#25 of 41

Top Ranked Stocks in Industry

View Top Medical Stocks

Be the first to know about important LMAT news, forecast changes, insider trades & much more!

LMAT News

Overview

Due Diligence Score

Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LMAT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LMAT ($79.00) is undervalued by 35.08% relative to our estimate of its Fair Value price of $121.69 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LMAT ($79.00) is significantly undervalued by 35.08% relative to our estimate of its Fair Value price of $121.69 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LMAT ($79.00) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more LMAT due diligence checks available for Premium users.

Valuation

LMAT fair value

Fair Value of LMAT stock based on Discounted Cash Flow (DCF)

Price
$79.00
Fair Value
$121.69
Undervalued by
35.08%
LMAT ($79.00) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LMAT ($79.00) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LMAT ($79.00) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LMAT price to earnings (PE)

For valuing profitable companies with steady earnings

Company
28.62x
Industry
45.57x
Market
14.23x
LMAT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LMAT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

LMAT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.44x
Industry
3.28x
LMAT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LMAT price to earnings growth (PEG)

For valuing profitable companies with growth potential

LMAT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

LMAT's financial health

Profit margin

Revenue
$66.6M
Net Income
$15.7M
Profit Margin
23.6%
LMAT's Earnings (EBIT) of $85.81M... subscribe to Premium to read more.
Interest Coverage Financials
LMAT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$629.5M
Liabilities
$222.9M
Debt to equity
0.55
LMAT's short-term assets ($477.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LMAT's short-term assets ($477.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LMAT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LMAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$15.1M
Investing
-$13.1M
Financing
-$3.2M
LMAT's operating cash flow ($87.31M)... subscribe to Premium to read more.
Debt Coverage Financials

LMAT vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LMATC$1.81B-25.32%28.62x4.44x
BLFS$1.65B+3.94%-563.33x4.44x
ATRCB$2.00B+0.87%187.33x3.87x
KMTSC$1.47B-3.36%-10.31x5.66x
AZTAC$1.47B+5.61%-8.22x0.94x

Lemaitre Vascular Stock FAQ

What is Lemaitre Vascular's quote symbol?

(NASDAQ: LMAT) Lemaitre Vascular trades on the NASDAQ under the ticker symbol LMAT. Lemaitre Vascular stock quotes can also be displayed as NASDAQ: LMAT.

If you're new to stock investing, here's how to buy Lemaitre Vascular stock.

What is the 52 week high and low for Lemaitre Vascular (NASDAQ: LMAT)?

(NASDAQ: LMAT) Lemaitre Vascular's 52-week high was $118.01, and its 52-week low was $78.65. It is currently -33.06% from its 52-week high and 0.45% from its 52-week low.

How much is Lemaitre Vascular stock worth today?

(NASDAQ: LMAT) Lemaitre Vascular currently has 22,850,739 outstanding shares. With Lemaitre Vascular stock trading at $79.00 per share, the total value of Lemaitre Vascular stock (market capitalization) is $1.81B.

Lemaitre Vascular stock was originally listed at a price of $6.20 in Oct 19, 2006. If you had invested in Lemaitre Vascular stock at $6.20, your return over the last 19 years would have been 1,174.19%, for an annualized return of 14.33% (not including any dividends or dividend reinvestments).

How much is Lemaitre Vascular's stock price per share?

(NASDAQ: LMAT) Lemaitre Vascular stock price per share is $79.00 today (as of Aug 5, 2026).

What is Lemaitre Vascular's Market Cap?

(NASDAQ: LMAT) Lemaitre Vascular's market cap is $1.81B, as of Aug 6, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lemaitre Vascular's market cap is calculated by multiplying LMAT's current stock price of $79.00 by LMAT's total outstanding shares of 22,850,739.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.